
Proteinase 3 (cANCA)
Myeloblastin
p29
AGP7
Size: 1.0mgSource: Human Neutrophils
Product Information:
Autoantibodies to proteinase 3 are found in the sera of patients with active Wegener's granulomatosis and less often in other types of systemic vasculitis including microscopic polyangiitis, idiopathic crescentic glomerulonephritis, Churg-Strauss syndrome and polyarteritis nodosa.
Proteinase 3 (PR3) is a serine proteinase with proteolytic activity towards a range of substrates. The protein has been described as having antibiotic and growth-promoting properties but has been noted to causing emphysema when administered by tracheal insufflation.
Proteinase 3 cDNA has been cloned and sequenced, revealing the protein to be a basic 25 kDa glycoprotein of 228 amino acids. The protein reveals a triplet of bands in the range 29-32 kDa when subjected to denaturing SDS-electrophoresis, probably caused by differing degrees of glycosylation. Although proteinase 3 shows significant homology to elastase and cathepsin G, cANCA sera do not cross react with these serine proteases.
Autoantibodies to PR3 appear to recognise conformational epitopes and have been reported to interfere with inactivation of the enzyme by α1-antitrypsin and to also inhibit proteolytic activity itself.
Proteinase 3 (cANCA) datasheet
Clinical Indications:
Vasculitic diseases
Wegener's Granulomatosis
MSDS
References:
Davies, D.J. et al. (1982) Br. Med. J. 285, 606
Wiik, A. et al. (1994) Man. Biol. Markers of Dis. (Kluwer Acad.Publ.) A9:1-14
Ludemann, J. et al. (1990) J. Exp. Med. 171, 357
Jenne, D.E. et al. (1990) Nature 346, 520
Gupta, S.K. (1990) Blood, 76, 2162
Wiik, A. (1995) Semin. Clin. Immunol. 9, 5
Kallenberg, C.G.M. et al. (1994) Kidney Int. 46, 1
Kam, C.M. et al. (1992) FEBS Lett. 297, 119
Dolman, K.M. et al. (1992) FEBS Lett. 314, 117
Campanelli, D. et al. (1990) J. Exp. Med. 172, 1709
Bories, D. et al. (1989) Cell 59, 959
Kao, R.C. et al. (1988) J. Clin. Invest. 82, 1963
Wieslander, J. & Wiik, A. (1994) Man. Biol. Markers of Dis.(Kluwer Acad. Publ.) B1:1-9
Goldschmeding, R. et al. (1989) J. Clin. Invest. 84, 1577
Nassberger, L. et al. (1993) Autoimmunity 14, 259
Bini, P. et al. (1992) J. Immunol. 149, 1409
Van den Wiel, A. et al. (1992) Clin. Exp. Immunol. 90, 409
Ludemann, J. et al. (1988) J. Immunol. Meth. 114, 167
Daha, M.R. et al. (1990) Neth. J. Med. 36, 117
Kallenberg, C.G.M. & Rasmussen, N. (1990) Neth. J. Med. 36,132
Gaskin, G. et al. (1995) J. Immunol. Meth. 180, 25
Stumann, L. & Wiik, A. (1997) J. Immunol. Meth. 206, 35
Heegaard, N.H.H. et al. (1997) Anal. Biochem. 253, 259
Hagen, E.C. et al. (1993) J. Immunol. Meth. 159,1
Hagen, E.C. et al. (1996) J. Immunol. Meth. 196, 1